Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418802 | 1.00 | NR4A2 (1.00) | NR4A2ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL1024142 | 0.84 | NR4A2 (0.73) | NR4A2ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL31499475 | 0.84 | NR4A2 (0.73) | NR4A2ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL2468811 | 0.83 | CYP1A2 (1.00) | NR4A2ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL29365003 | 0.83 | ALDH1A1 (1.00) | NR4A2ALDH1A1TSHRCYP3A4HPGD | |
| SCHEMBL29629127 | 0.83 | CYP1A2 (1.00) | NR4A2ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL48843 | 0.83 | ALDH1A1 (1.00) | NR4A2ALDH1A1TSHRCYP3A4HPGD | |
| Ammonia Solution, Strong SCHEMBL7197839 | 0.80 | ALDH1A1 (0.93) | NR4A2ALDH1A1TSHRCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL8641121 | 0.80 | CYP3A4 (0.93) | NR4A2ALDH1A1TSHRCYP3A4HPGD | |
| SCHEMBL335367 | 0.80 | ALDH1A1 (0.93) | NR4A2ALDH1A1TSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4216951-B1 | KRAS G12D INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4592295-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250154156-A1 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | SHENZHEN FORWARD PHARMACEUTICALS CO., LIMITED (CN) | 2025-05-15 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| EP-1319007-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2003-06-18 | — | — | EP | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2002024702-A1 | FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
| US-4268458-A | Process for the preparation of N-alkylated aromatic amines | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-19 | — | — | US | disclosed |
| US-4031106-A | Synthesis of aromatic amines by reaction of aromatic compounds with ammonia | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
| US-4001260-A | NICKEL-NICKEL OXIDE-ZIRCONIUM OXIDE AMINATION CATALYST | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | NR4A2 13/4885ALDH1A1 3219/4885TSHR 101/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | NR4A2 4644/4885ALDH1A1 1816/4885TSHR 4213/4885 |
| US-20260109714-A1 | PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | KRAS, NRAS, HRAS | NR4A2 338/4885ALDH1A1 1260/4885TSHR 2063/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | NR4A2 2643/4885ALDH1A1 2880/4885TSHR 439/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | NR4A2 3217/4885ALDH1A1 3319/4885TSHR 3724/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | NR4A2 3217/4885ALDH1A1 3319/4885TSHR 3724/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | NR4A2 3372/4885ALDH1A1 2554/4885TSHR 4405/4885 |
| US-20250154156-A1 | QUINAZOLINE DERIVATIVE AS KRAS G12C MUTATION INHIBITOR | KRAS, NRAS, HRAS | NR4A2 3989/4885ALDH1A1 1724/4885TSHR 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.